Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

We are a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases.

Our chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. Our pipeline is initially focused on neurological disorders and extends across several other therapeutic areas.

1 st

first to design and bring stereopure and
allele-specific medicines to clinic

3

clinical studies initiated in 2017

5

nucleic acid modalities being advanced with Wave stereopure chemistry

12+

discovery programs

 

Investor Relations

Recent News

Jan 24, 2019

Wave Life Sciences Prices $150 Million Public Offering of Ordinary Shares

CAMBRIDGE, Mass. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today the pricing of its previously announced underwritten

Jan 23, 2019

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares

CAMBRIDGE, Mass. , Jan. 23, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today that it has commenced an underwritten public offering of

Events

Recent News

Jan 24, 2019

Wave Life Sciences Prices $150 Million Public Offering of Ordinary Shares

CAMBRIDGE, Mass. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today the pricing of its previously announced underwritten

Jan 23, 2019

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares

CAMBRIDGE, Mass. , Jan. 23, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today that it has commenced an underwritten public offering of
Recent News and Events

Copyright West LLC. Minimum 15 minutes delayed.